Alnylam Pharmaceuticals’ (ALNY) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Friday,Benzinga reports. The firm currently has a $300.00 price target on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. HC Wainwright increased their price objective on Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $310.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Finally, Scotiabank lowered their price target on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a report on Friday, February 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $310.22.

Alnylam Pharmaceuticals Stock Up 11.8 %

ALNY stock opened at $283.34 on Friday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market capitalization of $36.68 billion, a price-to-earnings ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a fifty day moving average of $257.16 and a 200-day moving average of $259.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last ninety days. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. OneDigital Investment Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $281,000. Natixis Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $2,751,000. Mutual of America Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock valued at $529,000 after buying an additional 405 shares during the last quarter. Pathstone Holdings LLC raised its stake in Alnylam Pharmaceuticals by 11.2% during the third quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock valued at $1,719,000 after buying an additional 629 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $902,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.